Novartis loses patent battle in India: Time to realign the business model to emerging markets?

• Main Authors: REDDY, Srinivas K., LLEWELYN, David, MATHUR, Sarita
• Format: text
• Language: English
• Published: Institutional Knowledge at Singapore Management University 2013
• Subjects: Pharmaceuticals; Intellectual Property; IP; Emerging Markets; Novartis; Glivek; Drugs; Business Models; Ethics; Patenting; Big Pharma; Business Model Adaptation; Pricing; Pricing Strategies; Business Administration, Management, and Operations; Business Law, Public Responsibility, and Ethics; International Business; Marketing
• Online Access: https://ink.library.smu.edu.sg/cases_coll_all/54; https://cmp.smu.edu.sg/case/2601
• Institution: Singapore Management University

On April 1, 2013, the Supreme Court of India rejected Novartis’ patent application for its cancer treatment drug, Glivec. Novartis had applied for patent protection in 2006, and after a seven-year legal battle, it all ended in disappointment for the Swiss pharmaceutical company. Public opinion seeme...